NO20065196L - Terapeutisk kombinasjon for behandling av Alzheimers sykdom - Google Patents

Terapeutisk kombinasjon for behandling av Alzheimers sykdom

Info

Publication number
NO20065196L
NO20065196L NO20065196A NO20065196A NO20065196L NO 20065196 L NO20065196 L NO 20065196L NO 20065196 A NO20065196 A NO 20065196A NO 20065196 A NO20065196 A NO 20065196A NO 20065196 L NO20065196 L NO 20065196L
Authority
NO
Norway
Prior art keywords
disease
alzheimer
treatment
therapeutic combination
treating alzheimer
Prior art date
Application number
NO20065196A
Other languages
English (en)
Norwegian (no)
Inventor
Gregg H Larson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20065196L publication Critical patent/NO20065196L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO20065196A 2004-04-14 2006-11-13 Terapeutisk kombinasjon for behandling av Alzheimers sykdom NO20065196L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56214104P 2004-04-14 2004-04-14
PCT/IB2005/000923 WO2005099823A1 (en) 2004-04-14 2005-04-04 Therapeutic combination for treatment of alzheimers disease

Publications (1)

Publication Number Publication Date
NO20065196L true NO20065196L (no) 2007-01-03

Family

ID=34963723

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065196A NO20065196L (no) 2004-04-14 2006-11-13 Terapeutisk kombinasjon for behandling av Alzheimers sykdom

Country Status (14)

Country Link
EP (1) EP1737539A1 (enExample)
JP (1) JP2007532624A (enExample)
KR (1) KR20060133008A (enExample)
CN (1) CN1960781A (enExample)
AU (1) AU2005232447A1 (enExample)
BR (1) BRPI0509881A (enExample)
CA (1) CA2562069A1 (enExample)
IL (1) IL178120A0 (enExample)
MX (1) MXPA06011969A (enExample)
NO (1) NO20065196L (enExample)
RU (1) RU2006136361A (enExample)
TW (1) TW200533341A (enExample)
WO (1) WO2005099823A1 (enExample)
ZA (1) ZA200608239B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
JP7059192B2 (ja) * 2016-02-11 2022-04-25 シグマテラ・ソシエテ・パ・アクシオンス・シンプリフィエ 神経変性疾患の治療に使用するためのイグメシン
WO2020252475A1 (en) * 2019-06-14 2020-12-17 Atiba Joshua O Triple pharmaceutical composition for proteinaceous infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
ATE331523T1 (de) * 2002-04-02 2006-07-15 Janssen Pharmaceutica Nv Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EA012325B1 (ru) * 2002-12-24 2009-08-28 Беллус Хелс (Интернэшнл) Лимитед Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CA2516990A1 (en) * 2003-03-19 2004-09-30 Ares Trading S.A. Treatment of alzheimer's disease
US20050090449A1 (en) * 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
CN1960781A (zh) 2007-05-09
IL178120A0 (en) 2006-12-31
CA2562069A1 (en) 2005-10-27
AU2005232447A1 (en) 2005-10-27
TW200533341A (en) 2005-10-16
KR20060133008A (ko) 2006-12-22
RU2006136361A (ru) 2008-04-20
JP2007532624A (ja) 2007-11-15
EP1737539A1 (en) 2007-01-03
MXPA06011969A (es) 2006-12-15
ZA200608239B (en) 2008-06-25
WO2005099823A1 (en) 2005-10-27
BRPI0509881A (pt) 2007-10-16

Similar Documents

Publication Publication Date Title
EA200901373A1 (ru) Аминогетероциклические соединения
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
GB0223040D0 (en) Therapeutic compounds
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
NO20084362L (no) Difenylazetidinon derivater inneholdende kolesterol absorbsjonsinhibitor aktivitet
PL2526934T4 (pl) Inhibitory kinazy tyrozynowej Brutona
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE507204T1 (de) Isoindolin-verbindungen und deren verwendungen
NO20081421L (no) Midler for hindring og behandling av forstyrrelser som involverer modulering av RYR-reseptorer
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
NO20065196L (no) Terapeutisk kombinasjon for behandling av Alzheimers sykdom

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application